Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer

详细信息    查看全文

• 作者：Tobias Ach (1)
  Katharina Zeitler (2)
  Stephan Schwarz-Furlan (3)
  Katharina Baader (1)
  Abbas Agaimy (3)
  Christian Rohrmeier (4)
  Johannes Zenk (5)
  Martin Gosau (1)
  Torsten E. Reichert (1)
  Gero Brockhoff (6)
  Tobias Ettl (1)
  
• 关键词：Salivary gland cancer ; MET ; EGFR ; PTEN ; Prognosis
• 刊名：Virchows Archiv
• 出版年：2013
• 出版时间：January 2013
• 年：2013
• 卷：462
• 期：1
• 页码：65-72
• 全文大小：449KB
• 参考文献：1. Speight PM, Barrett AW (2002) Salivary gland tumours. Oral Dis 8:229-40 CrossRef
  2. Hara T, Ooi A, Kobayashi M et al (1998) Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization. Lab Invest 78:1143-153
  3. Masuya D, Huang C, Liu D et al (2004) The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients. Br J Cancer 90:1555-562 CrossRef
  4. Miller CT, Lin L, Casper AM et al (2006) Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma. Oncogene 25:409-18
  5. Birchmeier C, Birchmeier W, Gherardi E et al (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915-25 CrossRef
  6. Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-043 CrossRef
  7. Barnes L, Eveson JW, Reichart P et al (2005) Pathology and genetics of head and neck tumours. World Health Organization Classification of Tumours. IARC Press, Lyon, p 430
  8. Jouzdani E, Yachouh J, Costes V et al (2010) Prognostic value of a three-grade classification in primary epithelial parotid carcinoma: result of a histological review from a 20-year experience of total parotidectomy with neck dissection in a single institution. Eur J Cancer 46:323-31 CrossRef
  9. Therkildsen MH, Christensen M, Andersen LJ et al (1998) Salivary gland carcinomas—prognostic factors. Acta Oncol 37:701-13 CrossRef
  10. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-10 CrossRef
  11. Schwarz S, Stiegler C, Muller M et al (2011) Salivary gland mucoepidermoid carcinoma is a clinically, morphologically and genetically heterogeneous entity: a clinicopathological study of 40 cases with emphasis on grading, histological variants and presence of the t(11;19) translocation. Histopathology 58:557-70 CrossRef
  12. Cappuzzo F, Hirsch FR, Rossi E et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-55 CrossRef
  13. Cappuzzo F, Janne PA, Skokan M et al (2009) MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol 20:298-04 CrossRef
  14. Ettl T, Stiegler C, Zeitler K et al (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43:921-31 CrossRef
  15. Ettl T, Baader K, Stiegler C et al (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106:719-26 CrossRef
  16. Cooper CS, Park M, Blair DG et al (1984) Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311:29-3 CrossRef
  17. Appleman LJ (2011) MET signaling pathway: a rational target for cancer therapy. J Clin Oncol 29:4837-838 CrossRef
  18. Lal B, Goodwin CR, Sang Y et al (2009) EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts. Mol Cancer Ther 8:1751-760 CrossRef
  19. Suzuki S, Dobashi Y, Minato H et al (2012) EGFR and HER2-Akt-mTOR signaling pathways are activated in subgroups of salivary gland carcinomas. Virchows Arch 461:271-82 CrossRef
  20. Williams MD, Roberts DB, Kies MS et al (2010) Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin Cancer Res 16:2266-274 CrossRef
  21. Takami T, Kaposi-Novak P, Uchida K et al (2007) Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of / N-nitrosodiethylamine induced hepatocarcinogenesis. Cancer Res 67:9844-851 CrossRef
  22. Dziadziuszko R, Wynes MW, Singh S et al (2012) Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer. J Thorac Oncol 7:340-47 CrossRef
  23. Tsukinoki K, Yasuda M, Mori Y et al (2004) Hepatocyte growth factor and c-Met immunoreactivity are associated with metastasis in high grade salivary gland carcinoma. Oncol Rep 12:1017-021
  24. Suzuki K, Cheng J, Watanabe Y (2003) Hepatocyte growth factor and c-Met (HGF/c-Met) in adenoid cystic carcinoma of the human salivary gland. J Oral Pathol Med 32:84-9 CrossRef
  25. Klosek SK, Nakashiro K, Hara S, Shintani S, Hasegawa H, Hamakawa H (2005) CD151 forms a functional complex with c-Met in human salivary gland cancer cells. Biochem Biophys Res Commun 336:408-16 CrossRef
  26. Lennerz JK, Kwak EL, Ackerman A et al (2011) MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 29:4803-810 CrossRef
  27. Tanizaki J, Okamoto I, Okamoto K et al (2011) MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 6:1624-631 CrossRef
  28. Bean J, Brennan C, Shih JY et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104:20932-0937 CrossRef
  29. Benedettini E, Sholl LM, Peyton M et al (2010) Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177:415-23 CrossRef
  30. Arteaga CL (2007) HER3 and mutant EGFR meet MET. Nat Med 13:675-77 CrossRef
  31. Cepero V, Sierra JR, Corso S et al (2010) MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 70:7580-590 CrossRef
  32. Danilkovitch-Miagkova A, Zbar B (2002) Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J Clin Invest 109:863-67
  33. Qi J, McTigue MA, Rogers A et al (2011) Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res 71:1081-091 CrossRef
  34. Li Y, Guessous F, DiPierro C et al (2009) Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy. Mol Cancer Ther 8:376-85 CrossRef
  35. Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139-145 CrossRef
  36. Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-024 CrossRef
  37. Pandolfi PP (2004) Breast cancer—loss of PTEN predicts resistance to treatment. N Engl J Med 351:2337-338 CrossRef
  38. Agulnik M, Cohen EW, Cohen RB et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978-984 CrossRef
  39. Glisson BS, Blumenschein G, Francisco M et al (2005) Phase II trial on gefitinib in patients with incurable salivary gland cancer [abstract]. J Clin Oncol 23:5532
  40. Haddad R, Colevas AD, Krane JF et al (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39:724-27 CrossRef
  41. Locati LD, Bossi P, Perrone F et al (2008) Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 45:574-78 CrossRef
  42. Vidal L, Tsao MS, Pond GR et al (2009) Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib. Head Neck 31:1006-012 CrossRef
  43. Piha-Paul SA, Cohen PR, Kurzrock R (2011) Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus. J Clin Oncol 29:e727–e730 CrossRef
  
• 作者单位：Tobias Ach (1)
  Katharina Zeitler (2)
  Stephan Schwarz-Furlan (3)
  Katharina Baader (1)
  Abbas Agaimy (3)
  Christian Rohrmeier (4)
  Johannes Zenk (5)
  Martin Gosau (1)
  Torsten E. Reichert (1)
  Gero Brockhoff (6)
  Tobias Ettl (1)
  
  1. Department of Oral and Maxillofacial Surgery, University of Regensburg, Franz-Josef-Strau?-Allee 11, 93053, Regensburg, Germany
  2. Department of Pathology, University of Regensburg, Franz-Josef-Strau?-Allee 11, 93053, Regensburg, Germany
  3. Department of Pathology, University of Erlangen-Nuremberg, Krankenhausstra?e 8-10, 91054, Erlangen, Germany
  4. Department of Otorhinolaryngology, University of Regensburg, Franz-Josef-Strau?-Allee 11, 93053, Regensburg, Germany
  5. Department of Otorhinolaryngology, University of Erlangen-Nuremberg, Waldstra?e 1, 91054, Erlangen, Germany
  6. Department of Gynecology and Obstetrics, University of Regensburg, Landshuter Stra?e 65, 93053, Regensburg, Germany
  
• ISSN：1432-2307

文摘

Hepatocyte growth factor receptor (MET) is a key driver of oncogenic transformation. Copy number gain and amplification of MET positively enhance tumour growth, invasiveness and metastasis in different cancer types. In the present study, 266 carcinomas of the major and minor salivary glands were investigated for genomic MET status by fluorescence in situ hybridization and for protein expression by immunohistochemistry. Results were matched with clinicopathological parameters, long-term survival and the status of epidermal growth factor receptor (EGFR) and phosphatase and tensin homologue (PTEN). Low polysomy (n--2), high polysomy (n--7), amplification (n--) and deletion (n--8) were found as aberrations of genomic MET in certain subtypes. MET aberrations were associated with increased patient age (>70?years, p--.003), male gender (p--.01), increased tumour size (p--.002), lymph node metastases (p-lt;-.001), high-grade malignancy (p-lt;-.001) and unfavourable overall survival (p-lt;-.001). Both copy number gain (p-lt;-.001) and deletion (p--.031) of MET correlated with copy number gain of EGFR. Tumours with genomic loss of PTEN (n--8) concurrently presented aberration of genomic MET (p-lt;-.001). MET gene status significantly correlated with protein status (p--.038). In conclusion, gain but also loss of genomic MET activity correlates with aggressive tumour growth, nodal metastasis and worse overall survival in salivary gland cancer. Moreover, aberrations of MET are associated with EGFR and PTEN signalling and might possess relevance for targeted therapies of salivary gland carcinomas in the future.